Our results indicate that the TGFβ-Smad2/3 signaling pathway-induced EMT process is involved in GCB resistance in bladder cancer by transactivating Slug and ZEB2 and downregulating hCNT1 and hENT1. The gene discussed is SLC29A1; the disease is urinary bladder cancer.